← All trials
NCT06616961
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2024
- Primary completion
- Feb 28, 2025
- Completion date
- Oct 31, 2026
- First posted
- Sep 27, 2024
- Last posted
- Sep 27, 2024
- Enrollment
- 480
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Popular Medical College HospitalLead sponsor
- Incepta Vaccine LimitedCollaborator
- Popular Medical College HospitalSponsor investigator
- Pi Research Consultancy Center, BangladeshCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.